Novelix Pharmaceuticals, Inc., a Delaware corporation, is a private, California-based biotechnology company committed to developing proprietary, first-in-class, targeted small molecules for skin and cancer therapy. All of the Novelix small molecule drugs and platforms have been designed and created by the company’s founders and team members. Multiple Novelix compounds are also well suited for cosmeceutical use, providing additional high value opportunities with short development timelines.
Beyond its innovative compounds with strong IP positions (over 30 composition of matter patents have issued) and its experienced team, the company differentiates itself through its business model. Novelix is a “virtual company plus”. Novelix operates as a virtual company with a very low monthly burn. Plus, Novelix also leverages its many personal connections at top quality institutions so that with little or no cash outlay by the company, drug development and experimentation conducted by quality personnel at state-of-the-art facilities provide mission critical data and enhance our intellectual property value. The company further reduces risk by evaluating its drug candidates, not only in commonly used model systems, but also, in canine patients with spontaneously occurring diseases that more closely resemble conditions seen in humans. Recently, Novelix successfully completed a human pilot with one of its lead drug candidates.
Novelix has selected two lead product programs for further development.